Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 14, 2005 Brian Gorman	GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision.
The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool November 2, 2005 Brian Gorman	Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool November 9, 2005 Brian Gorman	Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
The Motley Fool June 13, 2005 Brian Gorman	Walgreen Strikes Back The traditional drugstore operator is expanding its mail-order business. This should be a welcome sign to investors.
The Motley Fool June 22, 2006 Stephen D. Simpson	Rite Aid: Not Quite Rad, but Not All Bad Better results are possible, but there might be better ideas for investors.
BusinessWeek March 7, 2005 Amy Barrett	A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool June 28, 2005 Mike Cianciolo	Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.
The Motley Fool April 19, 2011 Bryan White	Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies.
The Motley Fool July 30, 2009 Brian Orelli	A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money.
The Motley Fool April 27, 2005 Brian Gorman	Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
The Motley Fool July 6, 2007 Lawrence Rothman	Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
Managed Care September 2005 Martin Sipkoff	Mail Order Pharmacy Saves Money, Says PCMA, but at What Cost? The savings to consumers and employers are apparent, but are health plans left holding the bag in mail-order pharmacy?
The Motley Fool January 13, 2009 Dayana Yochim	Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions.
The Motley Fool June 30, 2011 David Williamson	Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool March 28, 2005 Alyce Lomax	A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?
The Motley Fool April 30, 2008 Brian Orelli	Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs.
The Motley Fool August 16, 2010 Brian Orelli	The Fine Line Between Saving Money and Making It Medco's trying to walk it.
The Motley Fool February 28, 2005 Brian Gorman	Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
The Motley Fool March 22, 2010 Dave Mock	A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst.
The Motley Fool October 29, 2009 Brian Orelli	Expressing Itself Nicely A nice quarter for Express Scripts.
The Motley Fool September 27, 2005 Nathan Slaughter	All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors.
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
The Motley Fool September 21, 2006 Vitaliy Katsenelson	Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.
The Motley Fool August 1, 2006 Selena Maranjian	Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.
PC Magazine August 19, 2003 Alan Cohen	Online Prescriptions With $1.4 billion in sales last year, Merck subsidiary Medco Health online is doing something right.
Managed Care October 2005	Health Plans Pay Less When PBM Owns Mail-Order Pharmacy The ongoing debate on whether health plans pay more for drugs when using a mail-order pharmacy owned by a pharmacy benefits manager (PBM) or when the mail-order pharmacy is not owned by a PBM may be closer to resolution.
The Motley Fool September 27, 2006 Michael P. Cecil	A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool November 3, 2010 Brian Orelli	A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it.
The Motley Fool July 6, 2007 Mike Cianciolo	Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.
The Motley Fool October 2, 2011 Shubh Datta	Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment?
The Motley Fool February 15, 2006 Stephen D. Simpson	Good Marks for Caremark The pharmacy benefits management company should have even more positive operating leverage left in the tank. Investors, take note.
The Motley Fool November 8, 2006 Michael P. Cecil	CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm.
The Motley Fool January 12, 2010 Dayana Yochim	6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab.
Managed Care November 2005 John Carroll	FTC Report Arms PBMs In Battle With Drugstores Congress passed the Medicare Modernization Act allowing pharmacy benefits managers to participate in Medicare Part D.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.